Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
H Wang, DU Yong, R Zhang, J Xu, L Liu - US Patent 8,431,132, 2013 - Google Patents
A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an
immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in …
immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in …
Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease
MR Silver, A Agarwal, M Krause, L Lei… - The American Journal of …, 2008 - Elsevier
Background: The anemia of chronic kidney disease (CKD) is associated with increased
hospitalizations, increased cardiovascular morbidity and mortality, and diminished quality of …
hospitalizations, increased cardiovascular morbidity and mortality, and diminished quality of …
Haemorrhage
B Norman - Crises in Childbirth-Why Mothers Survive, 2018 - taylorfrancis.com
In the Confidential Enquiries into Maternal Deaths (CEMD) report for 2000–2002 there were
17 deaths classified as directly due to haemorrhage, 11 deaths due to ectopic pregnancy …
17 deaths classified as directly due to haemorrhage, 11 deaths due to ectopic pregnancy …
[图书][B] Advancements in detection of performance enhancing drugs in dried blood spots: focusing on erythropoietin
CE Heiland - 2024 - openarchive.ki.se
The use of erythropoietin (EPO) for performance enhancing purposes is detected mainly in
urine and serum samples in anti-doping laboratories. However, dried blood spots (DBS) …
urine and serum samples in anti-doping laboratories. However, dried blood spots (DBS) …
Biotechnology-derived medicines: what are they? A pharmacological and a historical perspective
F De Mora, R Torres - Journal of Generic Medicines, 2010 - journals.sagepub.com
Biologicals, that is, medicines obtained from living organisms, are not new. History provides
many examples of animal or human extracts being used to prevent or treat human diseases …
many examples of animal or human extracts being used to prevent or treat human diseases …
[PDF][PDF] Efficacy and safety of ior® EPOCIM for chemotherapy-or radiotherapy-induced anemia in pediatric cancer patients
A Vargas, I Mendoza, R Uranga, A Gonzalez… - Medicc …, 2010 - medigraphic.com
ABSTRACT INTRODUCTION: Recombinant human erythropoietin (RHuEPO) is an
erythropoiesis stimulating agent (ESA) used to treat anemia in patients with total or relative …
erythropoiesis stimulating agent (ESA) used to treat anemia in patients with total or relative …
Polynucleotides encoding human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
H Wang, DU Yong, R Zhang, J Xu, L Liu - US Patent 7,964,375, 2011 - Google Patents
A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an
immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in …
immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in …
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
H Wang, Y Du, R Zhang, J Xu, L Liu - US Patent 10,117,949, 2018 - Google Patents
A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an
immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in …
immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in …
Cell line development for human erythropoietin with two additional N-links in CHO-DG44 cells
The development of cell lines for the production of therapeutic protein drugs is complex,
laborious, and expensive. However, due to the ever-increasing demand, the …
laborious, and expensive. However, due to the ever-increasing demand, the …